| 1. | SMITHKLlNE      BEECHAM CORPORATION (d.b.a. GlaxoSmithKline) a corporation having its      principal office at One Franklin Plaza, Philadelphia PA 19101, USA      ("GSK"); and |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | RESPONSE      GENETICS INC., a company incorporated in the State of Delaware, whose      principal place of business is situated at 1640 Marengo Street, Suite 600,      Los Angeles, CA 90033 ("RGI"). |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (A) | GSK      is a global innovative pharmaceutical company with extensive research and      development capabilities. |
|-----|-------------------------------------------------------------------------------------------------------------------|

| (B) | RGI      is engaged, inter alia, in the business of supplying Testing Services, as      that is defined herein, in relation to the pharmaceutical industry and      related industries and has considerable skill and knowledge in that      field. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (C) | In      reliance upon that skill, knowledge and experience, GSK wishes to engage      RGI as a preferred provider to provide services principally in relation to      profiling the expression of various genes from a range of human      malignancies and RGI agrees to accept preferred provider status and the      engagement on the following terms and  conditions. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1. | In      this Agreement the following expressions shall have the following      meanings: |
|--------|----|------------------------------------------------------------------------------------------|

|   | 1.1 | "Affiliate"      with respect to a person shall mean any other person that directly, or      indirectly through one of more intermediaries, controls, is controlled by      or is under common control with such person; for the purposes of this      clause 1.1 only, "control" and, with correlative meanings, the terms      "controlled by" and "under common control with", shall mean (a) the      possession, directly or indirectly, of the power to direct the management      or policies of a person, whether through the ownership of voting      securities, by contract or otherwise, and/or (b) the ownership, directly      or indirectly, of at least fifty percent (50%) of the voting securities or      other ownership interest of aperson: |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.2 | "Agreement"      means this Agreement between GSK and RGI for the supply of Services by      RGI. |
|--------|-----|---------------------------------------------------------------------------------------------------|

|   | 1.3 | "Confidential      Information" shall mean any and all commercial and technical information      relating to any of the existing or planned products, businesses, research      and/or development activities, customers and suppliers of either Party      whether in written, verbal or any other form, tangible or intangible,      which either Party may acquire or may have access from time to time,      provided such information is marked as "Confidential and Proprietary" and      provided that information which is orally disclosed shall be confirmed in      writing within 30 days from oral disclosure. Confidential Information      includes and is not limited to: (a) any information generated in      connection with the provision of the Services (such as the results or      findings thereof and the contents of any report) under this Agreement, (b)      information concerning inventions, discoveries, concepts, ideas,      techniques, processes, designs, specifications, drawings, diagrams,      models, samples, flow charts, computer programs, algorithms, data,      databases, studies, mathematical calculations, finances and plans,      customer lists, business plans, contracts, marketing plans, production      plans, distribution plans, system implementation plans, business concepts,      supplier information, business procedures and business operations and all      materials related thereto; (c) the existence, contents or terms of this      Agreement, (d) all know-how and intellectual property, (e) all unpublished      copyrightable material, (f) any use, variation, application, reduction to      practice, or any discussion and any other communication thereof regarding      or relating to the Information, and (g) any information concerning how any      part of the above information is related to and/or fits together with any      other part of the above information, or any other technology or business;      Notwithstanding the foregoing, the Parties agree that any and all data,      reports, laboratory work sheets, results, materials or information      provided by either Party or its Affiliates or Third Parties on behalf of a      Party and any other documents or information furnished to a Party, or to      which a Party is given access, by the other Party or its Affiliates or      such Third Parties in connection with the performance of this Agreement,      or prepared or generated by a Party in connection with performing any and      all Studies hereunder, shall be deemed to be the Confidential Information      of the Party which owns such disclosed  information. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.4  | "Effective      Date" means the date first givenabove; |
|--|-----------|--------------------------------------------------------|

|   | 1.5 | "Party"      shall mean GSK or RGI as the context requires and "Parties" shall mean      both GSK and RGI; |
|--------|-----|------------------------------------------------------------------------------------------------------------|

|   | 1.6 | "Person"      and words importing persons shall be construed as to include individuals,      firms, bodies corporate, joint ventures, governments, states or agencies      of state or any undertaking (whether or not having separate legal      personality and irrespective of the jurisdiction in or under the laws of      which it was incorporated orexists); |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.7 | "Purpose"      shall mean the provision of the Services pursuant to this Agreement and      the evaluation by the Parties of whether to add other projects and      services to this Agreement; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.8 | "Relevant      Staff" shall mean employees and sub-contractors involved in providing the      Services and named in the relevant Schedule or otherwise agreed to in      writing by GSK; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.9 | "Services"      means the services to be provided by RGI pursuant to this Agreement (as      amended from time to time in accordance with the provisions of this      Agreement) and such other services as may from time to time be agreed upon      by RGI and GSK, including Testing Services, FISH/IHC testing      services, TLDA testing services, consultation and tissue storage, in      connection with this Agreement and as further detailed and agreed upon in      a SOW pursuant to Article 1 below; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.10 | "Term"      means that this Agreement shall commence on the Effective Date and shall      continue until 17 January 2011  ("Initial Term"), unless sooner      terminated in accordance with the provisions hereof, renewable at the      option of, and upon the agreement of both Parties in additional one (1)      year increments ("Renewal Term");and |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.11. | "Testing      Services" means RGl's business, among other things, of conducting      molecular-based tumor tissue profiling using a proprietary and patented      process developed by RGI which involves a complex molecular analysis of      specific molecular markers that provides valuable tumor specific gene      expression information obtained from a paraffin preserved fresh or frozen      tissue sample, which can help the physician choose the most appropriate      therapy for a patient prior to starting treatment or assist a      pharmaceutical company in Identifying the appropriate candidate patient      population suitable for a therapy in development. Testing Services      includes TLDA TestingServices. |
|--|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | 1.12 | "Third      Party" shall mean any Person who is not a Party hereto or any of their      Affiliates, References to recitals, clauses and, if applicable, schedules      are to the recitals and clauses of and, if applicable, the schedules to,      this Agreement. To the extent that there is conflict between or ambiguity      relating to any schedules to this Agreement and the remainder of this      Agreement, the wording of the schedules shall  prevail. |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.13 | “FISH/IHC      Testing Services” means molecular-based tumor tissue profiling [***]      fluorescence in situ hybridization analysis of molecular markers of gene      expression obtained from a tissue sample.  For the avoidance of      doubt, FISH/IHC Testing Services shall not be deemed part of “Testing      Services. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.14 | “Analytical      Services” means the evaluation and analysis of bioinformatics data,      including the analysis and interpretation of gene expression data or other      data, related to the performance or results related to the Testing      Services or FISH/IHC TestingServices. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.15 | “TLDA      Testing Services” means RNA isolation using a proprietary and patented      extraction process developed by RGI from paraffin embedded tumor samples      or fresh frozen tumor samples and qRT-PCR analysis using the TLDA      system. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 1.16 | “Preferred      Provider” means RGI has met the preferred provider specifications      [***] |
|--------|------|----------------------------------------------------------------------------------------------------------|

| 2. | References      to recitals, clauses and, if applicable, schedules are to the recitals and      clauses of and, if applicable, the schedules to, this      Agreement.  To the extent that there is conflict between or      ambiguity relating to any schedules to this Agreement and the remainder of      this Agreement, the wording of the schedules shall  prevail. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Any      schedules to this Agreement form part of this Agreement and shall have the      same force and effect as if expressly set out in the body of the Agreement      and any reference to the Agreement shall include the schedules. Schedules      may not be added to this Agreement except by the express written consent      of both Parties. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4. | Words      denoting the singular shall include the plural and vice versa and words      denoting any gender shall include all genders unless the context otherwise      requires. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5. | A      reference to any Party shall include a reference to the legal successors      to the whole or a substantial part of its undertaking and its permitted      assignees. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6. | References      to any statute or statutory provision shall, unless the context otherwise      requires, be construed as a reference to that statute or provision as from      time to time amended, consolidated, modified, extended, re-enacted or      replaced. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7. | The      headings preceding the text of the various provisions of this Agreement      are for convenience of reference only and are not intended to, nor do      they, define, limit or in any other way describe the scope of this      Agreement or the intent of the provisions  hereof. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.1  |  Statement      of Work |
|--|-----------|------------------------------|

|  | 1.1.1 | RGI      agrees to perform a study or studies which will involve Testing Services      (hereinafter referred to as "Study") from time to time in accordance with      a Statement of Work in the form of Exhibit B attached hereto ("SOW"), for      the benefit of GSK or any Affiliate of GSK. Each SOW shall include as      attachments (i) a detailed Protocol document ("Protocol") which shall be      provided by GSK or prepared by RGI under GSK's direction and approved in      writing by GSK, and which shall be attached to each SOW as Schedule I, and      (ii) a pricing schedule in the form of Schedule Il to the SOW attached      hereto ("Pricing Schedule"). An SOW shall not be effective unless it has      been agreed upon in writing by bothParties. |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.1.2 | The      Pricing Schedule for the Testing Services shall be based upon the Testing      Services Fee Schedule set forth in Exhibit A. The Pricing Schedule for the      FISH/IHC Testing Services shall be based upon the FISH/IHC Testing      Services Fee Schedules set forth in Exhibit A-1. The Pricing Schedule for      the Analytical Testing Services shall be based upon the Analytical Testing      Services Fee Schedules set forth in Exhibit A-2. The Pricing for the TLDA      Testing Services shall be based upon the TLDA Testing Services Fee      Schedule set forth in Exhibit A-3. Each SOW shall specify the Study      design, information desired, estimated duration of the applicable Study,      milestones and reporting (if applicable) and all other relevant matters      pertinent to completion of such Study (except for pricing), and shall be      deemed a part of this Agreement and is incorporated herein by reference.      Each Pricing Schedule attached to a SOW shall specify the cost to GSK of      the Services RGI is to perform in connection with such Study and shall be      deemed a part of this Agreement and is incorporated herein by      reference. |
|--|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 1.1.3 | If      requested by GSK, RGI shall consult with GSK to assist GSK in developing      any Study design in a manner consistent with current regulatory      guidelines. RGI represents that any such Study design and/or the results      from any such Study shall satisfy the requirements of the U.S. Food and      Drug Administration ("FDA") and the European Medicines Agency ("EMEA") at      the time the Study design iscompleted. |
|--|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.2  | Study      Director |
|--|-----------|---------------------|

|  | 1.2.1 | RGI      shall appoint a study director ("Study Director") to be responsible to      oversee the completion of each Study by RGI. The Study Director shall      coordinate performance of the applicable Study with a representative      designated by GSK ("GSK Representative"), which GSK Representative shall      have responsibility over all matters relating to the performance of such      Study on behalf of GSK. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.2.2 | Unless      otherwise agreed to in the applicable SOW, or by the Study Director and      GSK Representative, all communications between RGI and GSK regarding the      conduct of each Study pursuant to a SOW shall be addressed to or routed      directly through the applicable Study Director and GSK Representative. RGI      may substitute its Study Director and GSK may substitute the GSK      Representative, as the case may be, during the course of a particular      Study by providing written notice thereof to the other    Party. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 1.3  | Corrective      Measures |
|--|-----------|--------------------------|

|  | 1.3.1 | If,      at any time during the term of this Agreement, RGI becomes aware that the      applicable SOW was not followed, or that RGI otherwise made a material      error or mistake in conducting Testing Services, RGI agrees to notify GSK      of such occurrence in writing promptly following the day such discovery is      made. Upon receipt of such notice, GSK will notify RGI in writing, within      a reasonable time, whether corrective measures which may include retesting      are required to ensure validity of results, and GSK will not be invoiced      for any necessary corrective measures. RGI agrees to promptly implement      necessary corrective measures. The retest data will be reported by RGI to      GSK within a reasonable time from the receipt by RGI of notification from      GSK that retesting is required. |
|--|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 2.1 | This      Agreement will commence with effect, as defined herein, from the Effective      Date and will continue for the Term, as defined in this Agreement, or      until terminated in accordance with the provisions of Article      9.  The parties shall have the right, but not the obligation, to      extend the Term for one-year periods ("Renewal Term") beyond the initial      Term by mutually agreeing in writing prior to expiration of the      Term. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 2.2 | Notwithstanding      the foregoing, however, such Term shall continue in force with respect to      all Studies being conducted under SOWs which have an effective date prior      to the expiration of the term of this Agreement, until all such Studies      have been completed, and the final report and any other pertinent      Study-related documents for such Studies have been received by and      completed to the reasonable satisfaction of GSK. All references in this      Agreement to "Term of this Agreement" shall be deemed to include both the      initial Term and any Renewal Terms. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 3.1 | GSK      agrees to pay RGI according to the payment schedule set forth in the      Pricing Schedule as part of the SOW. The Pricing Schedule shall be based      on the unit pricing provided in Exhibits A, A1, A2 and A3 and shall      specify the timing of the issuance of invoices applicable to the SOW.      Absent an alternative arrangement agreed upon by the Parties for a      particular SOW, RGl may issue invoices to GSK on a quarterly basis for      Services provided pursuant to the Agreement. All payments due hereunder      shall be paid by GSK net thirty (30) days upon receipt by GSK of an      accurate, complete invoice. Absent terms in the SOW to the contrary,      nothing in this Agreement shall be interpreted to require RGI to initiate      any SOW or to require GSK to pay for work conducted pursuant to any SOW      prior to the execution of the relevant SOW by RGI.   RGI      shall be entitled to interest at the rate of prime plus one percent for      any payments not timely made to it under this Agreement. In the event that      GSK contests the validity or accuracy of amounts invoiced to it under the      Agreement, no interest payments shall be required for amounts later      determined to have been inappropriately invoiced. Prices and fees set      forth in this Agreement will remain fixed during the Initial      Term. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 3.2 | GSK      will pay RGI in consideration of the Services performed pursuant to this      Agreement the following; |
|--|-----|-----------------------------------------------------------------------------------------------------------------|

|  | 3.2.1 | For      microdissection of tumor or normal tissue and isolation of RNA or DNA, GSK      shall pay a fee of [***] persample. |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------|

----

|  | 3.2.2 | For      Services, GSK shall pay according to the fee schedule set forth in      Exhibits A, A-1, A-2 and A-3hereto. |
|--|-------|----------------------------------------------------------------------------------------------------------------------|

|  | 3.2.3 | Samples      may include pre- and post-treatment biopsies as well as adjacent normal      tissue excised from samples sent for analysis. Pre- Post- and Normal are      considered three different types ofsamples. |
|--|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 3.2.4 | Samples      provided for analysis must meet mutually agreed upon specified criteria      for tumor content and slide preparation which includes, but is not limited      to, providing compliance with sample preparation instructions, and      compliance with packaging, delivery and shipping requirements and      instructions. RGI will make reasonable efforts to pre-screen the samples      for sufficiency prior to analysis and if RGI in its discretion eliminates      insufficient or deficient samples prior to performing any analysis, RGI      will not charge GSK for that sample. Assuming that the samples provided by      GSK for analysis meet agreed upon specified criteria, RGI agrees to      extract RNA from at least [***] of the samples, calculated on an      annual basis. If RGI is unable to extract RNA from at least [***] of      the samples that meet RGl's criteria, calculated on an annual basis, GSK      shall not be charged for those samples from which RGI was unable to      extract RNA. If RGI is able to extract RNA from at least [***] of the      samples that meet RGl's criteria, calculated on an annual basis, GSK shall      nevertheless be charged for all samples if the non-conformance to RGI      criteria could not have reasonably been determined by RGI without having      performed the analysis first. |
|--|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 3.2.5  | Samples,      for the purposes of this Agreement, may include samples from any      GSK-funded source or sponsored samples deemed of interest to      GSK. |
|--|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  |   | 3.3GSK      agrees to make a non-refundable Upfront Payment of $1,300,000 on or before      December 31, 2008. This payment of $1,300,000 may be credited against      future work undertaken in the period beginning on January 1, 2009 and      ending on December 31, 2010. (the “Credit Period”.  If GSK      submits samples to RGI during the Credit Period which generate payment      obligations exceeding the Upfront Payment, then GSK shall make payment to      RGI in the amount which exceeds the Upfront Payment.  If GSK      sends samples to RGI during the Credit Period which do not generate      payment obligations sufficient to meet the amount of the Upfront Payment,      RGI shall retain the excess amount. |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.1 | RGI      shall provide a turnaround time of no longer than two (2) months for      performance of Testing Services for retrospective samples delivered to RGI      in that time period, subject to the conditions set forth in ¶ 4.2      herein.  If requested in advance by GSK, RGI shall provide a      turnaround time of seven (7) business days for performance of RT-PCR      Testing Services (up to 6 genes plus a housekeeping gene) for up to a      maximum of [***] prospective samples delivered to RGI in that time      period, on the condition that any such samples shall be subject to      a [***] surcharge over the fees set forth in Exhibit A. If more      than [***] prospective samples are provided in any seven (7) business      day time period, RGI shall turnaround the excess above [***] in the      next 7 business day period, and the [***]      surcharge shall also apply to such samples.  Such excess samples      shall be included in the [***] sample maximum for the next 7 business      day period. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.2 | To      assist RGI to expeditiously perform the Testing Services, GSK will use      reasonable efforts to evenly distribute samples sent to RGI for testing      throughout each quarter and year. If samples for anyone quarter will      exceed [***] GSK shall provide RGI notice of how many samples it      expects to deliver and of what mutually agreeable genes it will be      requesting analysis of at least two (2) quarters in advance to allow RGI      sufficient time to supplement resources (personnel, equipment, materials,      etc.) or to develop probes or primers, as necessary, in order to analyze      the samples expected. If GSK provides such notice to RGI, then GSK shall      make best efforts to deliver to RGI for testing samples equaling the      estimated sample number. If GSK does not provide such samples for testing,      RGI and GSK shall discuss and negotiate in good faith to compensate RGI      for any unused investments RGI made in anticipation of such      samples. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.3 | RGI      will perform the Testing Services. in compliance  with the      applicable laws, regulations, and guidelines governing the performance of      the Testing Services, including those relating to Good Laboratory      Practices, CAP and CLIA. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.4 | RGI      shall use reasonable efforts to provide facilities, supplies and staff      necessary to complete each Study as provided in the applicable SOW, as it      may be modified as provided herein, and in accordance with the terms of      this Agreement. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 4.5 | GSK's      representatives may visit RGl's laboratory and premises at reasonable      times, on reasonable prior notice, and with reasonable frequency during      normal business hours to observe the progress of any Study, and any and      all information and results derived therefrom. RG I shall assist GSK in      scheduling such visits. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.6 | All      reports prepared by RGI hereunder shall be prepared in a format specified      in the applicable SOW. GSK shall have access to all documentation,      records, raw data, specimens or other work product generated during the      performance of each Study. RGI agrees to maintain appropriate records in      paper or magnetic form, in a manner which complies with regulatory      requirements. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.7 | RGI      agrees to comply with all provisions of the Generic Drug Enforcement Act      of 1992. RGI further agrees to submit to GSK, upon request upon completion      or termination of the Testing Services, a certification that neither RGI      nor any of its employees has been debarred by the FDA under the provisions      of the Act and that RGI did not use in any capacity in connection with the      Testing Services any individual debarred by the FDA under the provisions      of the above referenced Act. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.8 | Should      applicable government regulatory requirements be changed during the term      of this Agreement, RGI shall make reasonable efforts to satisfy the new      requirements. In the event that compliance with such new regulatory      requirements necessitates a change in the SOW for a Study, RGI shall      submit to GSK a revised technical and cost proposal for GSK's acceptance      prior to making any changes in the SOW for such  Study. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.9 | In      the event of a conflict in government regulations, GSK shall, upon request      by RGI, designate which regulations shall be followed by RGI in Its      performance of a particular Study. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.10 | RGI      agrees to use reasonable care in safeguarding, inventorying and handling      all SOW data, materials and supporting documentation (hereinafter      collectively termed "Study Archives") originating from any SOW conducted      under this Agreement by RGI, whether written or physical (such as      notebooks, original or raw data, protocols, interim or final report      copies). The Study Archives shall be considered to be Confidential      Information of GSK. RGI will maintain the samples provided to it for      testing under this agreement in accordance with the usual and customary      standards for maintaining such materials. Upon request by GSK, RGI will      provide sample materials to GSK or a copy of documents from the Study      Archives, at GSK's expense. To the extent that samples are transferred to      GSK, responsibility for maintaining such samples will then be undertaken      by GSK. The samples and Study Archives are to be retained and archived by      RGI for a period of not less than ten (10) years following the completion      of the relevant SOW. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.11 | Following      the end of the relevant ten (10) year retention period, RGI further agrees      that no samples or records originating from any Services conducted under      this Agreement and retained in RGl's possession as Study Archives will be      permanently disposed of or destroyed by RGI without the prior written      permission of GSK. GSK agrees that such written permission will not be      unreasonably withheld; provided, however, that in lieu of the granting of      permission for such disposal, GSK shall have the right at the time such      permission for disposal is requested by RGI to claim such materials and to      have RGI transmit such materials to GSK, by a carrier of GSK's choice and      at GSK's expense. In the event RGI requests such permission to dispose of      the samples or Study Archives from GSK under the provisions of notice      contained in this Agreement, and no response is received from GSK within      four (4) weeks, RGI shall be deemed to have received from GSK permission      for permanent disposal. |
|--|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.12 | GSK      may, at a reasonable time upon reasonable prior notice, obtain access to      the samples and Study Archives, provided that GSK complies with RGI's      reasonable access and control procedures relating to such      materials. |
|--|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.13 | RGI      represents that each of its personnel, employees, agents, representatives,      subcontractors or invitees who shall perform any Study hereunder shall      abide by the provisions of Article 4 hereof. RGI agrees that each of its      personnel, employees, agents, representatives, subcontractors or invitees      who shall perform any Study hereunder shall be at least eighteen (18)      years old or legal age, whichever isolder. |
|--|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4.14 | GSK      hereby appoints RGI as a preferred provider for the services which are      subject to this agreement.[***] |
|--|------|----------------------------------------------------------------------------------------------------------------------|

|  | 5.1 | Save      as otherwise provided in this Agreement, any Confidential Information      which is disclosed by or on behalf of either Party (the "Disclosing      Party") to the other Party (the "Receiving Party") at any time after the      date of this Agreement shall remain the property of the Disclosing Party      and the Receiving Party herebyundertakes: |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 5.1.1 | To      use the Confidential Information received from the Disclosing Party and      subject to the provisions of Section 6 hereto, solely and exclusively for      the Purpose; and |
|--|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.1.2 | To      maintain the confidentiality of the Confidential Information and not to      disclose it directly or indirectly to any other company, organization,      individual or Third Party, save as permitted by clause 5.2;      and |
|--|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.1.3 | At      the request of the Disclosing Party to return, delete or destroy all      copies of the Confidential information, in whatever form it is held,      provided that the Receiving Party may retain one copy of the Confidential      Information for the sale purpose of determining its obligations under this      Agreement but may make no further use of such Confidential Information      whatsoever. |
|--|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.2 | Notwithstanding      clause 5.1, if RGI is the Receiving Party, it may disclose Confidential      Information to any of its Relevant Staff who need to know the Confidential      Information in order to fulfill the Purpose, provided that RGI shall      procure that each such person to whom or which Confidential Information is      to be disclosed: |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.2.1 | is      made aware of the obligations contained in this Agreement prior to such      disclosure; and |
|--|-------|------------------------------------------------------------------------------------------------------|

|  | 5.2.2  | agrees      to abide by such terms of this Agreement as if it were a Party to      it. |
|--|-------------|----------------------------------------------------------------------------------------|

|  | 5.3 | Nothing      in clause 5.1 shall preclude disclosure of any Confidential Information      required by any governmental, quasi-governmental or regulatory agency or      authority or court entitled by law to disclosure of the same, or which is      required by law to be disclosed. The Receiving Party shall promptly notify      the Disclosing Party when such requirement to disclose has arisen to      enable the Disclosing Party to seek an appropriate protective order and to      make known to the said agency or authority or court the proprietary nature      of the Confidential Information and to make any applicable claim of      confidentiality in respect thereof. The Receiving Party agrees to      co-operate in any appropriate action which the Disclosing Party may decide      to take. If the Receiving Party is advised to make a disclosure in      accordance with this clause 5.3 it shall only make a disclosure to the      extent to which it is obliged. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.4  | The      provisions of clause 5.1 shall not apply to any Confidential Information      which:- |
|--|-----------|------------------------------------------------------------------------------------------------|

|  | 5.4.1 | The      Receiving Party can demonstrate by its written records, was already in the      possession of the Receiving Party and at its free use and disposal or      generally and conveniently available to the public prior to its disclosure      by the Disclosing Party hereunder (through in each case no fault of the      Receiving Party or any of its Affiliates or no breach of this Agreement by      the Receiving Party); or |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.4.2 | Is      purchased or otherwise legally acquired by or becomes available to the      Receiving Party at any time from a Third Party which is not prohibited      from disclosing such Confidential Information;  or |
|--|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.4.3 | Comes      into the public domain, otherwise than through the fault of the Receiving      Party or at the time of disclosure is in the public domain;    or |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.4.4 | The      Receiving Party can demonstrate by its written records was developed by or      for the Receiving Party independently of the disclosure of Confidential      Information by the Disclosing Party or its  Affiliates. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.5 | The      obligations of each Party in this clause 5 shall survive for a period of      ten years from the date of disclosure of such  information. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5.6 | Each      of the Parties agrees that damages may not be an adequate remedy for      breach of this clause 5 and that, accordingly, each Party shall be      entitled to seek injunctive or other equitable  relief. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.1 | Except      as otherwise provided herein, all title to any and all inventions,      improvements and data, whether or not patentable, and copyrightable works,      which result from the performance of any Study hereunder shall reside with      GSK, subject to the remaining provisions of this Article  6. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 6.2 | RGI      will make reasonable efforts to disclose to GSK all inventions and      improvements (whether patentable or not) and all copyrightable works made      by it which are governed by Section 6.1. RGI agrees, upon GSK's written      request, to cooperate at GSK's expense in formally assigning title to GSK      to such inventions, improvements and copyrightable works, and to assist      GSK in obtaining patent or copyright protection to such intellectual      property. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.3 | Subject      to the remaining provisions of this Article 6, RGI agrees that all      original works of authorship prepared by or for RGI in the performance of      any Study hereunder shall be works for hire, and GSK shall own such works      and all copyrights therein. For any original such works of authorship      that, under the copyright laws of the United States, may not be considered      works for hire, RGI agrees to reasonably cooperate with GSK in protecting      its rights in such works. Such works shall be deemed to be the property of      GSK, and shall be included in the Confidential Information of GSK under      this Agreement. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.4 | RGI      owns, and GSK acknowledges RGl's ownership of, (i) the Testing Services,      including RGl's proprietary process for analyzing the samples and      producing the gene expression values, and all of the materials which      comprise same, and any accompanying patent information owned by RGI, (ii)      all intellectual property associated therewith (the "Intellectual      Property"), and (iii) any algorithms or scales created and used by RGI in      producing or developing the gene expression values ("algorithms"), and      agrees that it shall not do or suffer to be done any act or thing or      undertake any action anywhere that in any manner might infringe, or impair      the validity, scope, or title of RGI in the Testing Services, algorithms      or Intellectual Property which may be owned by RGI at any time. It is      understood that neither GSK nor any Affiliate shall acquire or claim title      to the Testing Services, algorithms, research and development, or the      Intellectual Property by virtue of this Agreement, including any      improvements or modifications thereto which are developed during the      course of RGI's performance under the Agreement, the Parties intending      that all utilization of the Testing Services, algorithms and relating      Intellectual Property by GSK shall at all times inure to the exclusive      benefit of RGI. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.5 | For      the avoidance of doubt, the gene expression values produced and/or      developed by the Testing Services ("gene expression values"), as well as      all designs, developments, ideas, discoveries, inventions and information      designed, developed, discovered, invented, produced or originated by GSK      independent of RGI in the course of or as a result of GSK's use or      analysis of the gene expression values provided to GSK by RGI pursuant to      this Agreement shall be the sole property of GSK. All such designs,      developments, ideas, discoveries, inventions and information shall be part      of the Confidential Information of GSK. In the event GSK decides, at its      discretion, to seek patent, copyright or other protection (whether in the      United States or elsewhere) in relation to any of same, or to publish the      gene expression values, GSK shall acknowledge RGI's ownership of the      property set forth in clause 6.4, that the Testing Services and process by      which the gene expression values were produced are proprietary to RGI, and      that the gene expression values were produced using RGI's proprietary      process. RGI shall reasonably cooperate with GSK in the filing of any      necessary applications and in otherwise applying for, obtaining or      maintaining patent, copyright or other protection subject to GSK's      acknowledgement, as set forth in this paragraph, and to GSK bearing all      necessary costs and expenses in relation  thereto. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.6 | RGI      shall be entitled to utilize the gene expression values (although GSK      retains ownership of the gene expression values) only for the purposes of      this Agreement, and any designs, developments, ideas, discoveries,      inventions and information designed, developed, discovered, invented,      produced or originated by RGI independent of GSK in the course of or as a      result of RGI's use of the gene expression values provided to GSK by RGI      pursuant to this Agreement shall be the sole and absolute property of GSK.      All such designs, developments, ideas, discoveries, inventions and      information shall be part of the Confidential Information of GSK. RGI      shall reasonably cooperate with GSK in the filing of any necessary      applications and in otherwise applying for, obtaining or maintaining      patent, copyright or other protection with regard to any such designs,      developments, ideas, discoveries, inventions and information, subject to      GSK bearing all necessary costs and expenses in relation      thereto. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.7 | The      Parties will observe all copyright in written material, including computer      software, belonging to the other Party or any third Party, will not make      any unauthorised copies of such material or  software. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.8 | Each      Party acknowledges that the other Party owns certain inventions,      processes, know-how, trade secrets, improvements and other intellectual      property which have been independently developed by each Party and which      relate to that Party's business or operations. It is acknowledged that the      intellectual property owned by either Party on the date of this Agreement      will remain the exclusive property of the owning  Party. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 6.8.1 | GSK      shall provide RGI with sufficient amounts of all compounds, materials,      samples or other substances (collectively, the "Test Materials") with      which to perform each Study, as well as sufficient and comprehensive data      as may be reasonably required by RGI concerning the stability, proper      storage and safety requirements with respect to such Test Materials. Such      Test Materials shall remain the property of GSK at all times, shall be      used by RGI solely for purposes of performing this Agreement and shall be      properly stored by RGI in accordance with the SOW or as otherwise agreed      by the Parties. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 6.8.2 | Upon      completion of any Study, upon request by GSK, any remaining untested      samples of the Test Materials provided for such Study shall be returned to      GSK for retention in compliance with applicable regulatory      requirements. |
|--|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 7.1 | It      is understood that in the performance of this Agreement that RGI will be      acting in the capacity of an independent contractor and that nothing in      this Agreement shall be construed as creating any contract of employment      or relationship of principal and agent between GSK and RGI or GSK or any      of the Relevant Staff. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 7.2 | RGI      shall perform this Agreement solely as an independent contractor, and as      such shall select, engage and discharge its employees and otherwise direct      and control the performance of the Studies. Neither RGI nor anyone      employed by it shall be, represent, act, or purport to act as, or be      deemed to be, the agent, representative, employee, or servant of GSK nor      shall GSK nor anyone employed by it be, represent, act, or purport to act      as, or be deemed to be, the agent, representative, employee, or servant of      RGI. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 7.3 | Neither      GSK nor RGI shall have authority to make any statement, representation, or      commitment of any kind or to take any action binding upon the other Party      without the other Party's prior written  authorization. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 8.1  | RGI      represents and warrants that RGI and the Relevant  Staff: |
|--|-----------|--------------------------------------------------------------------|

|  | 8.1.1 | Have      the appropriate level of expertise and qualifications and the necessary      ability to undertake the work required under this Agreement;      and |
|--|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 8.1.2 | Are      not prevented or restricted by any obligations owed to a third Party or      otherwise in any way from performing the  Services. |
|--|-------|-------------------------------------------------------------------------------------------------------------------------------------------|

|  | 8.2 | Each      Party represents and warrants that it has the right to enter into this      Agreement and is not in conflict with any third Party obligation during      the performance of the Study under this  Agreement |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 8.3 | In      addition to any other indemnification provided herein, RGI agrees to      indemnify, defend and hold GSK and its affiliates, shareholders, officers,      directors, employees, agents, successors and assigns harmless from and      against any and all claims, suits, actions, liabilities, losses, costs,      reasonable attorneys' fees, expenses, judgments or damages, whether      ordinary, special or consequential (collectively, the "Indemnified      Amounts"), arising out of (i) RGI's negligence in the performance of any      Study, (ii) any wrongful acts or omissions in the performance by RGI of      any Study, whether such actions are of RGI, its employees, agents,      representatives, subcontractors or invitees or (iii) any material breach      of this Agreement by RGI, its employees, agents, representatives,      subcontractors or invitees. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 8.4 | In      addition to any other indemnification provided herein, GSK agrees to      indemnify, defend and hold RGI and its affiliates, shareholders, officers,      directors, employees, agents, successors and assigns harmless from and      against any and all Indemnified Amounts arising out of (i) GSK's      negligence in the conduct of the activities to be performed by GSK under      this Agreement, (ii) any wrongful acts or omissions in the conduct of the      activities to be performed by GSK under this Agreement, whether such      actions are of GSK, its employees, agents, representatives, subcontractors      or invitees or (iii) any material breach of this Agreement by GSK, its      employees, agents, representatives, subcontractors or      invitees. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 8.5 | Where      claims relate to those by third Parties and in the event either Party      incurs, or expects to incur expenses, damages, claims or liability for      which it intends to seek indemnification from the other Party, the Party      claiming indemnification (the "Indemnitee") shall promptly notify the      other Party (the "Indemnitor") and shall permit the Indemnitor, at the      Indemnitor's sole discretion, to settle any such claim or suit and agrees      to the compiete control of the defense or settlement of such claim or suit      by the Indemnitor, and the Indemnitor shall not be responsible for any      legal fees or other costs incurred other than as provided in this      Agreement. The Indemnitee, its employees, consultants and agents, shall      cooperate fully with the Indemnitor and its legal representatives in the      investigation and defense of any claims or suits covered by the      indemnification provisions of thisAgreement. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 9.1 | Either      Party ("the Non-Defaulting Party") may terminate this Agreement by notice      in writing if (a) the other Party commits or permits a material breach of      this Agreement which is incapable of remedy, or if capable of remedy, the      breaching Party fails to cure that breach within ninety (90) days of      receiving written notice thereof from the Non-Defaulting Party; or (b) the      other Party ceases to exist as a going concern as a result of bankruptcy      or insolvency. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 9.2 | In      the event of termination of this Agreement and/or any Study performed      under this Agreement, RGI shall use all reasonable efforts to minimize any      further costs and RGI shall be reimbursed only for the Services actually      performed and the expenses actually and reasonably incurred as of the      effective date of such termination, unless the parties agree or RGI is      otherwise obliged to provide Services after such      termination.  In the event of termination, any remaining credit      from the Upfront Payment shall remain withRGI. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 9.3 | Upon      termination of this Agreement, if requested by the other Party, each Party      shall immediately deliver up to the other Party or, if the other Party      agrees, destroy all copies of and other embodiments of any of the      Confidential Information and all other correspondence, documents,      specifications, and any other property belonging to the other Party which      may be in its/his/her possession. One archival copy of such materials may      be maintained in the possession of legal counsel for the      Party. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 9.4 | Articles      5, 6, 7, 12, 13, 15, and 17 shall survive termination of this Agreement      for whatever reason. |
|--|-----|-----------------------------------------------------------------------------------------------------------------|

|  | 9.5 | The      Parties may terminate this Agreement at any time by mutual agreement in      writing, executed by both Parties. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------|

|  | 10.1 | In      this Agreement, "force majeure" shall mean any cause preventing either      Party from performing any or all of its obligations which arises from or      is attributable to acts, events, omissions or accidents beyond the      reasonable control of the Party so prevented including, without      limitation, strikes, lock-outs or other industrial disputes (whether      involving the workforce of the Party so prevented or of any third Party),      act of God, war, terrorism, riot, civil commotion, malicious damage,      compliance with any law or Governmental order, rule, regulation or      direction, accident, breakdown of plant or machinery, fire, flood or storm      (each a "Force Majeure Condition"). Subject to clause 10.3, each Party      shall be released from its obligations under this Agreement to the extent      that its performance hereunder is delayed, hindered or prevented by force      majeure. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.2 | If      either Party is prevented or delayed in the performance of any of its      obligations under this Agreement by force majeure, that Party shall      forthwith serve notice in writing on the other Party specifying the nature      and extent of the circumstances giving rise to force majeure, and shall      subject to service of such notice and to clauses 10.3 and 10.4, have no      liability in respect of the performance of such of its obligations as are      prevented by the force majeure event during the continuation of such      events, and for such time after they cease as is necessary for that Party,      using all reasonable endeavors, to recommence its affected operations in      order for it to perform itsobligations. |
|--|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.3 | The      Party claiming to be prevented or delayed in the performance of any of its      obligations under this Agreement by reason of force majeure shall use all      reasonable endeavors to bring the force majeure event to a close or to      find a solution by which the Agreement may be performed despite the      continuation of the force majeureevent. |
|--|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.4 | If      either Party is prevented from performance of its obligations for a      continuous period in excess of three (3) months due to force majeure, the      other Party may terminate this Agreement forthwith on service of written      notice upon the Party so prevented, in which case neither Party shall have      any liability to the other except that rights and liabilities which      accrued prior to such termination shall continue to    subsist. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 10.5 | Notwithstanding      anything in this provision 10 to the contrary, no Force Majeure Condition      shall relieve GSK of the obligation to pay for Testing Services which have      already been completed by RGI. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1 | Any      notice required by this Agreement to be given to either Party shall be in      writing and shall be served by being addressed to the address of the other      Party stated in this Agreement or such other address as may from time to      time have been notified by a notice given in accordance with this clause.      Any notice or other document to be given under this Agreement shall be      deemed to have been duly given if left at or sent to the address, or If      more than one is listed, to the addresses, referred to in clause 11.2      by: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 11.1.1  | hand      or courier; |
|--|--------------|-----------------------|

----

|  | 11.1.2  | first      class post, express or other fast postal service (airmail if abroad);      or |
|--|--------------|------------------------------------------------------------------------------------------|

|  | 11.1.3  | registered      post; or |
|--|--------------|--------------------------|

|  | 11.1.4  | facsimile      or other electronic media. |
|--|--------------|-------------------------------------------|

|  | 11.1.5  | Any      such notice or other document shall be deemed to have been received by the      addressee two (2) working days following the date of dispatch of the      notice or other document by post (five (5) working days, if sent by      airmail) or, where the notice or other document is sent by hand or courier      or is given by facsimile or other electronic media, simultaneously with      the delivery or transmission. To prove the giving of a notice or other      document it shall be sufficient to show that it was      dispatched. |
|--|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 11.1.6  |  The      initial details for the purposes of clause 11.1  are: |
|--|--------------|----------------------------------------------------------------------|

----

|  | 12.1 | This      Agreement will be governed by and construed in accordance with the laws of      the State of New York, without regard to its conflict of laws or choice of      laws principles. The Parties agree that any disputes arising under this      Agreement shall be presented exclusively before the State Courts for the      State of New York or the Federal District Courts of New York. Each Party      hereby submits itself to the personal jurisdiction and venue of such      courts in connection with any such proceedings, and agrees to accept      service of process by mail. |
|--|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 13.1 | This      Agreement sets out the entire agreement and understanding between the      Parties regarding the subject matter of this Agreement and supersedes all      prior discussions, arrangements and agreements, whether oral or in writing      or which may be inferred from the conduct of the  Parties. |
|--|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 13.2 | No      other terms and conditions (including any standard terms and conditions of      GSK, RGI or their Affiliates) shall apply in relation to this Agreement or      the provision of the Services or of any other Services by RGI to GSK, save      for any additional terms and conditions specifically agreed to in writing      hereafter by the Parties. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 13.3 | Any      amendment or modification to this Agreement shall be made in writing and      signed by both Parties. |
|--|------|----------------------------------------------------------------------------------------------------------------|

|  | 14.1 | The      invalidity or unenforceability of any provision of this Agreement shall      not affect the validity or enforceability of any other provision, which      shall remain in full force and effect. The Parties shall use their      reasonable efforts to achieve the purpose of the invalid provision by a      new legally valid stipulation. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 15.1  | Either      Party may assign this Agreement in whole or in  part. |
|--|------------|-------------------------------------------------------------------|

|  | 16.1 | The      failure of either Party to exercise any right or remedy under this      Agreement shall not be deemed to be a waiver of such right or remedy. Any      waiver in respect of any breach of any provision of this Agreement which      is made in writing shall be valid but shall not be construed to be a      waiver of any succeeding breach of such a  provision. |
|--|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 17.1 | Neither      Party shall publish the existence or subject matter of this Agreement      without the prior written consent of the other Party, such consent not to      be unreasonably withheld or delayed. RGI may report to the U.S. Securities      and Exchange Commission (“SEC”) any information regarding this Agreement      which it reasonably deems advisable or  necessary. |
|--|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 17.2 | No      oral or written release of any statement, information, advertisement or      publicity matter having any reference to either GSK or RGI, express or      implied, shall be used by the other Party or on the other Party's behalf,      unless and until such matter shall have first been submitted to and      received the approval in writing of the Party whose name is being      used. |
|--|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 18.1  | RG      I shall obtain and pay for all permits, governmental fees, and licenses      necessary for the Studies to be performed hereunder and shall obtain all      required inspections, authorizations and approvals prior to commencement      of any Study hereunder. |
|--|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | 19.1 | RGI      agrees to maintain for a period of two years after the termination or      expiration of this Agreement adequate records of, and copies of all      receipts for expenses incurred in connection with, the performance of the      Services and allow access to GSK and its authorised representatives to      inspect such records and receipts upon reasonable  notice. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 20.1 | GSK's      representatives may visit RGI's facilities at reasonable times, on      reasonable prior notice, and with reasonable frequency, during normal      business hours to observe the progress of the Testing Services. RGI will      assist GSK in scheduling suchvisits. |
|--|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 21.1 | At      GSK's request, a representative of RGI shall accompany GSK to FDA to      explain or discuss any and all aspects of the Testing Services. Such visit      or visits to the FDA shall be arranged at times mutually agreeable to GSK      and RGI. All reasonable travel and living expenses incurred by RGI in      connection with such visits shall be reimbursed by  GSK. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 21.2 | RGI      shall notify GSK of any request from FDA, other federal or state agencies      or any other Third Party to inspect or otherwise gain access to the      information, gene expression values, clinical samples, or materials      pertaining to the services performed by RGI under this Agreement. RGI      shall notify GSK of such request prior to permitting any Third Party      access, unless prior notice is not reasonably  feasible. |
|--|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 21.3 | RGI      agrees to permit inspection of such information, gene expression values,      clinical samples, or other materials by authorized representatives of FDA      and as otherwise required by law. During such inspections, RGI shall      provide appropriate scientific and quality assurance support. RGI shall      promptly send GSK a copy of any inspection reports received by RGI as a      result of any such inspection. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 22.1 | This      Agreement may be executed in any number of counterparts, each of which      shall be deemed an original but all of which together shall constitute one      and the same instrument. |
|--|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 23.1 | Any      Exhibit or SOW to this Agreement is hereby incorporated into and made a      part of this Agreement. In the event of a conflict between the provisions      contained in this Agreement and any such Exhibit or SOWs, the terms of the      Agreement shall prevail over the Exhibit or SOW, except to the extent an      Exhibit or SOW specifically states that one of its provisions supersedes a      similar provision in the Agreement. |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                                                                       | Signature |   | Date   |                     |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------|--------|--------------------------------------------------------------------------------------|--------|
| Name:                                                                                                                                            |      |   |   |                                                                                 |   |
| Title:                                                                                                                                           |      |   |   |                                                                                 |   |
| SmithKline      Beecham Corporation                                                                                                              |      |   |   |                                                                                 |   |
|                                                                                                                                             |      |   |   |                                                                                 |   |
| Signed      for and on behalf of Response Genetics Inc. by                                                                                       |      |   |   |                                                                                 |   |
|                                                                                                                                             |      |   |   |                                                                                 |   |
|                          | Signature |   | Date   |                     |   |
| Kathleen      Danenberg                                                                                                                          |      |   |   |                                                                                 |   |
| Chief      Executive Officer                                                                                                                     |      |   |   |                                                                                 |   |
| Response      Genetics Inc.                                                                                                                      |      |   |   |                                                                                 |   |

----

| Research Service [***] | Cost/[***]                  | Explanation of      Service |
|------------------------|-----------------------------|-----------------------------|
| [***] [***]       | [***]                       | [***] [***]            |
| [***][***]             | [***]                       | [***]                       |
| [***]                  |
| [***]                  | [***]                       | [***]                       |
| [***]                  | [***] [***]            | [***] [***]            |
| [***]                  | [***]                       |                        |
| [***]                  | [***]                       | [***]                       |
| [***]                  | [***]                       | [***][***][***]             |
| [***]                  | [***] [***] [***] |                        |
| [***]                  |        -               |        -               |

----

| FISH/IHC | Cost  | Explanation      of Services |
|----------|-------|------------------------------|
| [***]    | [***] | [***]                        |
| [***]    | [***] | [***]                        |
| [***]    | [***] | [***]                        |
| [***]    | [***] | [***]                        |
| [***]    | [***] | [***]                        |

----

----

| [***] Services | Cost                           | Explanation      of Service |
|---------------------|--------------------------------|-----------------------------|
| [***]               | [***] $[***]/Sample  | [***]                       |

----

----

| RGI                                                                                              |                                                                           |        | SMITHKLlNE      BEECHAM CORPORATION |
|--------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------|-------------------------------------|
|                                                                                             |                                                                           |        | (d.b.a.      GlaxoSmithKline        |
|                                                                                             |                                                                           |        |                                |   |
| By:                                                                                              |                              |        | By:                                 |      |
| [Signature]                                                                                      |                                                                           | [Signature] |
|                                                                                             |                                                                           |        |                                |   |
| Name:                                                                                            |               |        | Name:                               |                   |
| [Print]                                                                                          |                                                                           |        | [Print]                             |
|                                                                                             |                                                                           |        |                                |   |
| Title:                                                                                           |               |        | Title:                              |            |
|                                                                                             |                                                                           |        |                                |   |
| Date:                                                                                            |                    |        | Date:                               |                   |
|                                                                                             |                                                                           |        |                                |   |
| AGREED      AND ACCEPTED:                                                                        |                                                                           |        |                                |
|                                                                                             |                                                                           |        |                                |   |
|                  |                                                                           |        |                                |
| Study      Director                                                                              |                                                                           |        |                                |

----

|                                 |         |
|--------------------------------------------------------------------|--------------------------------------------|
| Client      Representative                                         | Date                                       |
|                                                               |                                       |
|                  |              |
| Study      Director                                                | Date                                       |

----

| Milestone | Payments(US      $) | Approx.      % of total | Projected      date | For      Adminuse      only |
|-----------|---------------------|-------------------------|---------------------|-----------------------------|
| [***]     |                |                    |                |                        |
| [***]     |                |                    |                |                        |
| [***]     |                |                    |                |                        |
| [***]     |                |                    |                |                        |

| 1.      “INVOICE” stated      at the top                                |
|-------------------------------------------------------------------------------------|
| 2.      Supplier/Vendor’s Invoice Number and Date                             |
|   3. GlaxoSmithKline       GSK Information [***][***][***][***][***] |
| 4.      For electronic payment*: Bank Account Name/Address and Routing      details |
| 5.      Tax ID number or SS# **                                                     |
| 6.      Detailed description of Services or Contract  Milestone***                  |
| 7.      Amount of invoice                                                           |
| [***][***][***]                                                                     | All checks shall be made payable      to:Response      Genetics, Inc.1640      Marengo Street, 6th FloorLos      Angeles, CA 90033 |

----